Quantcast

Latest cocaine addiction Stories

2010-05-12 11:44:10

Treatment for cocaine addiction, improved anti-HIV measure part of week-long program Advancement in the treatment of cocaine overdoses and a new defense in the fight against HIV are just two examples of the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The conference takes place Sunday, May 16 -Thursday, May 20 at the Hilton San Francisco Union Square in San Francisco, Calif. A Possible...

2010-04-13 09:49:00

CORAL GABLES, Fla., April 13 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies...

2010-04-09 07:03:00

CORAL GABLES, Fla., April 9, 2010 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of...

2010-04-01 07:03:00

CORAL GABLES, Fla., April 1 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009. "In 2009, we transformed Catalyst into a multi-product company with compounds that have potential to address a variety of diseases...

2010-02-23 07:03:00

CORAL GABLES, Fla., Feb. 23 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (NasdaqCM: CPRX) announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide...

2009-10-01 16:58:00

CORAL GABLES, Fla., Oct. 1 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that it has entered into definitive agreements to sell 3.97 million shares of its common stock at a price per share of $1.00 pursuant to a registered direct offering to several select institutional investors, representing gross proceeds of $3.97 million. The closing of the offering is expected to take place on or about October 6, 2009, subject to the satisfaction of...

2009-09-30 15:03:00

CORAL GABLES, Fla., Sept. 30 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that the Company will continue to develop CPP-109 (Catalyst's version of vigabatrin) for the treatment of cocaine and methamphetamine addiction. The Company's decision was made after, and based upon, an in-depth review of the results obtained from its 186-patient Phase II clinical trial evaluating the use of CPP-109 for the treatment of cocaine addiction...

2009-09-23 07:22:43

Mizzou Scientists predict brain mechanisms must undergo alteration for addicts to recover About 2 million Americans currently use cocaine for its temporary side-effects of euphoria, which have contributed to making it one of the most dangerous and addictive drugs in the country. Cocaine addiction, which can cause severe biological and behavioral problems, is very difficult to overcome. Now, University of Missouri researchers Ashwin Mohan and Sandeep Pendyam, doctoral students in the...

2009-05-29 05:00:00

Management will host Conference Call at 9:00 AM ET Today CORAL GABLES, Fla., May 29 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint -- that a significantly larger proportion of CPP-109-treated subjects than placebo-treated subjects were cocaine-free...

2009-05-18 23:52:55

U.S. researchers have found cocaine regulated molecular pathways that may lead to addiction treatments. The study, published in Cell Press, finds long-lasting changes in behavior are elicited as cocaine regulates gene expression in a crucial reward region of the brain. Although we have known for some time that changes in gene expression contribute to the long-lasting regulation of the brain's reward circuitry that is seen during drug addiction, how those specific genes are regulated is not...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related